<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275363</url>
  </required_header>
  <id_info>
    <org_study_id>HKUNCDC</org_study_id>
    <nct_id>NCT03275363</nct_id>
  </id_info>
  <brief_title>The University of Hong Kong Neurocognitive Disorder Cohort</brief_title>
  <official_title>The University of Hong Kong Neurocognitive Disorder Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dementias Platform UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HKU Neurocognitive Disorder (NCD) Cohort is a hospital-based, prospective, observational
      study of older HK Chinese adults with cognitive impairment, with a special focus on studying
      patients with subjective cognitive decline and mild cognitive impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HKU Neurocognitive Disorder (NCD) Cohort is a hospital-based, prospective, observational
      study of older HK Chinese adults with cognitive impairment, with a special focus on studying
      patients with subjective cognitive decline and mild cognitive impairment, and in particular
      the biomarkers that predict cognitive and functional decline.

      Comprehensive profiling of each subject is performed through a multi-domain assessment
      protocol including detailed demographics, lifestyle factors, neuropsychological battery,
      mood, MRI, genetics, blood biomarkers, and other patient-centred parameters including level
      of disability, quality of life and societal engagement. Ongoing annual follow up captures the
      essential clinical events and changes in neurocognitive function (conversion to MCI or
      dementia), mood, level of disability and quality of life; as well as repeat blood tests.

      The HKU NCD Cohort is the first-ever Asian dementia cohort to be formally included into the
      Dementia Platforms UK, achieving an international collaborative status with other UK-based
      cohorts. The study neuropsychological battery is aligned with the NACC UDS3 battery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2014</start_date>
  <completion_date type="Anticipated">January 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Cognitive decline</measure>
    <time_frame>1 year</time_frame>
    <description>Change in total HK-MoCA score between baseline and follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional decline</measure>
    <time_frame>1 year</time_frame>
    <description>Change in Lawton's IADL score between baseline and follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric decline</measure>
    <time_frame>1 year</time_frame>
    <description>Change in Neuropsychiatric Index (NPI) between baseline and follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life decline</measure>
    <time_frame>1 year</time_frame>
    <description>Change in QoL-AD score between baseline and follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive impairment status</measure>
    <time_frame>1 year</time_frame>
    <description>Progression to mild cognitive impairment (MCI) or dementia status</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Neurocognitive Disorder</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer Dementia</condition>
  <condition>Vascular Dementia</condition>
  <condition>Age-related Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>Cognitively normal controls (CNC)</arm_group_label>
    <description>No subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjective cognitive decline (SCD)</arm_group_label>
    <description>Subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild cognitive impairment (MCI)</arm_group_label>
    <description>Subjective memory complaints Low HK-MoCA Normal instrumental ADL All interventions as described</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer's dementia</arm_group_label>
    <description>Subjective memory complaints Low HK-MoCA Poor instrumental ADL Probable Alzheimer's disease All interventions as described except EEG with ERP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vascular dementia</arm_group_label>
    <description>Subjective memory complaints Low HK-MoCA Poor instrumental ADL Related to stroke / cerebrovascular disease All interventions as described except EEG with ERP</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Neurocognitive battery</intervention_name>
    <description>Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted).
NACC: Story recall, Benson's complex figure copy, colour trail test (black &amp; white), verbal fluency, digit forward and backward span.</description>
    <arm_group_label>Cognitively normal controls (CNC)</arm_group_label>
    <arm_group_label>Subjective cognitive decline (SCD)</arm_group_label>
    <arm_group_label>Mild cognitive impairment (MCI)</arm_group_label>
    <arm_group_label>Alzheimer's dementia</arm_group_label>
    <arm_group_label>Vascular dementia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients</description>
    <arm_group_label>Cognitively normal controls (CNC)</arm_group_label>
    <arm_group_label>Subjective cognitive decline (SCD)</arm_group_label>
    <arm_group_label>Mild cognitive impairment (MCI)</arm_group_label>
    <arm_group_label>Alzheimer's dementia</arm_group_label>
    <arm_group_label>Vascular dementia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood tests</intervention_name>
    <description>Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis</description>
    <arm_group_label>Cognitively normal controls (CNC)</arm_group_label>
    <arm_group_label>Subjective cognitive decline (SCD)</arm_group_label>
    <arm_group_label>Mild cognitive impairment (MCI)</arm_group_label>
    <arm_group_label>Alzheimer's dementia</arm_group_label>
    <arm_group_label>Vascular dementia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>EEG with event-related potential (ERP)</intervention_name>
    <description>128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients</description>
    <arm_group_label>Cognitively normal controls (CNC)</arm_group_label>
    <arm_group_label>Subjective cognitive decline (SCD)</arm_group_label>
    <arm_group_label>Mild cognitive impairment (MCI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Amyloid PET CT</intervention_name>
    <description>F18 Flutametamol PET CT for selected patients</description>
    <arm_group_label>Subjective cognitive decline (SCD)</arm_group_label>
    <arm_group_label>Mild cognitive impairment (MCI)</arm_group_label>
    <arm_group_label>Alzheimer's dementia</arm_group_label>
    <arm_group_label>Vascular dementia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood at baseline and at yearly follow up
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Older adults with or without neurocognitive disoder. HKU NCD Cohort focuses primarily on
        people with Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older adults with or without neurocognitive disoder. HKU NCD Cohort focuses primarily
             on people with Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI).

        Exclusion Criteria:

          -  Severe Parkinson's disease, major depressive disorder or severe psychiatric
             conditions, significant communication difficulties (e.g. aphasia, deafness), terminal
             cancer or likely end-of-life in the next 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph SK Kwan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph SK Kwan, MD</last_name>
    <phone>+85222554769</phone>
    <email>jskkwan@hku.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlene Cheng, BA</last_name>
    <phone>+85222554769</phone>
    <email>cychar@hku.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Medicine, Queen Mary Hospital, The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph SK Kwan, MD</last_name>
      <phone>+85222554769</phone>
      <email>jskkwan@hku.hk</email>
    </contact>
    <contact_backup>
      <last_name>Charlene Cheng, BA</last_name>
      <phone>+85222554769</phone>
      <email>cychar@hku.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <link>
    <url>http://hub.hku.hk/cris/rp/rp01868</url>
    <description>Profile of PI</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr Joseph SK Kwan</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Subjective cognitive decline</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Dementia</keyword>
  <keyword>Cerebral aging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Neurocognitive Disorders</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Share with Dementias Platform UK (www.dementiasplatform.uk)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

